National Register for Adults with Moderate to Severe Atopic Dermatitis
Registro Nazionale Della Dermatite Atopica Moderata e Severa Nell'Adulto
This study is collecting information from adults with moderate to severe atopic dermatitis to better understand the condition and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse Academic / other |
| Locations | 1 site (Brescia, Brescia) |
| Trial ID | NCT06313333 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect clinical history and treatment data from adults suffering from moderate to severe atopic dermatitis (AD). It focuses on understanding the prevalence and characteristics of AD in adulthood, including cases that begin in adulthood or persist from childhood. The study will gather epidemiological and clinical data to help establish diagnostic criteria and improve treatment pathways for patients with adult-onset AD. By creating a national register, the study seeks to enhance the understanding of this condition and its impact on patients' quality of life.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with moderate to severe atopic dermatitis.
Not a fit: Patients who are unable to provide informed consent or are already participating in another follow-up register for atopic dermatitis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic criteria and treatment strategies for adults with atopic dermatitis.
How similar studies have performed: While there is ongoing research in atopic dermatitis, this specific approach of creating a national register for adult cases is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Age 18 years
2. Signature of informed consent
3. Diagnosis of moderate and/or severe DA by a dermatologist specialist defined on the basis of following criteria (10):
* EASI 16
* EASI \<16 but with at least one of the following conditions:
1. location in at least one of the following "critical" locations: face, hands, genitals
2. QID \> 10
3. VAS itching \> 7
4. VAS sleep \> 7
Exclusion Criteria:
1. Patient unable to provide informed consent prior to any collection procedures data on the study;
2. unable to complete the procedures required for the study;
3. a patient already participating in another follow-up register of the same disease.
Where this trial is running
Brescia, Brescia
- ASST Spedali Civili di Brescia — Brescia, Brescia, Italy (Recruiting)
Study contacts
- Principal investigator: Piergiacomo MD Calzavara Pinton — Asst Degli Spedali Civili Di Brescia
- Study coordinator: Piergiacomo MD Calzavara Pinton
- Email: piergiacomo.calzavarapinton@unibs.it
- Phone: 0303995305
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.